Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Journal of Clinical & Experimental OncologyISSN: 2324-9110
Sara Gebril Author
Subjects of specialization
Affiliation
Mucoepidermoid carcinoma, Cancer chemotherapy, Prostate biomarker
Department of Chemistry and Biochemistry, Faculty of Science, Mansoura University, Mansoura, Egypt
Biography
Sara Gebril was working in the Department of Chemistry and Biochemistry, Faculty of Science, Mansoura University, Mansoura, Egypt. Doctor has more than 40 publications. Doctor's current research area related to clinical oncology.
Publications
Research Article Open Access
Safe Combination of Cisplatin and Metformin Reverts the Malignant Ascites in a Mouse Model to a Solid Tumor by Downregulation of ΔNp63 and Induces Tumor Dormancy via m TOR/ p21 Mechanism
Author(s): Sara Gebril, Om-Ali Elkhawaga
Currently, combination therapy has become the cornerstone of cancer treatment. The combination of different anti-cancer mechanisms can induce tumor cell quiescence. However, toxicity to normal tissue is the major limitation of existing combined drugs. In this study, Ehrlich ascites carcinoma (EAC) inoculated into mice was targeted with just one dose of cisplatin and later doses of metformin, a safe anti-diabetic drug with an anti-cancer effect, to maintain EAC cells in the quiescent state and secure a longer survival time without tumor recurrence. The group that underwent dual therapy had developed a delayed solid tumor instead of a malignant ascites. Induction of chemo-quiescence in the EAC cells was proven by downregulation of mechanistic target of rapamycin (mTOR) and upregulation of... view more»
Google Scholars / Researchers Sites
